Malignancy in Myelofibrosis Patients Receiving Ruxolitinib Therapy

A Restrospective Study of Secondary Malignancies in Myelofibrosis Patients Receiving Ruxolitinib Therapy Myelofibrosis (MF) is a chronic, rare, and often fatal type of blood cancer characterized by a progressive replacement of bone marrow with fibrous scar tissue. This type of myeloproliferative neoplasm (MPN) leads to progressive spleen enlargement, systemic symptoms such

Tool for evaluating real world evidence in treatment of retinal disease

Tool for Evaluating RWE in the Treatment of Retinal Disease   Randomized clinical trials have long been held as the gold standard for evidence based medical practices. However, there is a growing consciousness about the value of incorporating data from real world-based evidence (RWE) into clinical decision making. Information from real world sources such

Malignancy in Myelofibrosis Patients Receiving Ruxolitinib Therapy